Renzo Carlucci

Dr. Renzo Carlucci

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
RCRenzo Carlucci
Renzo Carlucci
GGGabriel Di Gresia
Gabriel Di Gresia
MMMaría Gabriela Mediavilla
María Gabriela Mediavilla
JCJulia Alejandra Cricco
Julia Alejandra Cricco
BTBabu L. Tekwani
Babu L. Tekwani
GLGuillermo Roberto Labadie
Guillermo Roberto Labadie
We have previously shown that prenyl and aliphatic triazoles are interesting motifs to prepare new chemical entities for antiparasitic and antituberculosis drug development. In this opportunity a new series of prenyl-1,2,3-triazoles were prepared from isoprenyl azides and different alkynes looking for new antimalarial drug candidates. The compounds were prepared by copper(I) catalyzed dipolar cycloaddition of the isoprenyl azide equilibrium mixture providing exclusively 1,4-disubstituted 1,2,3-triazoles in a regiospecific fashion. The complete collection of 64 compounds was tested on chloroquine-sensitive (CQ sensitive), Sierra Leone (D6), and the chloroquine-resistant, Indochina (W2), strains of Plasmodium falciparum and those compounds which were not previously reported were also tested against Leishmania donovani, the causative agent for visceral leishmaniasis. Thirteen analogs displayed antimalarial activity with IC50 below 10 μM, while the antileishmanial activity of the newly reported analogs could not improve upon those previously reported. Compounds 1o and 1r were identified as the most promising antimalarial drug leads with IC50 below 3.0 μM for both CQ-sensitive and resistant P. falciparum strains with high selectivity index. Finally, a chemoinformatic in silico analysis was performed to evaluate physicochemical parameters, cytotoxicity risk and drug score. The validation of a bifunctional farnesyl/geranylgeranyl diphosphate synthase PfFPPS/GGPPS as the potential target of the antimalarial activity of selected analogs should be further investigated.

Verified
Journal Article
Open access
PDF file
JIJaime Ariel Isern
Jaime Ariel Isern
RCRenzo Carlucci
Renzo Carlucci
GLGuillermo Roberto Labadie
Guillermo Roberto Labadie
Exequiel O. J. PortaExequiel O. J. Porta
Exequiel O. J. Porta
Parasitic diseases represent a severe global burden, with current treatments often limited by toxicity, drug resistance, and suboptimal efficacy in chronic infections. This review examines the emerging role of triazole-based compounds, originally developed as antifungals, in advanced antiparasitic therapy. Their unique structural properties, particularly those of 1,2,3- and 1,2,4-triazole isomers, facilitate diverse binding interactions and favorable pharmacokinetics. By leveraging innovative synthetic approaches, such as click chemistry (copper-catalyzed azide–alkyne cycloaddition) and structure-based design, researchers have repurposed and optimized triazole scaffolds to target essential parasite pathways, including sterol biosynthesis via CYP51 and other novel enzymatic routes. Preclinical studies in models of Chagas disease, leishmaniasis, malaria, and helminth infections demonstrate that derivatives like posaconazole, ravuconazole, and DSM265 exhibit potent in vitro and in vivo activity, although their primarily static effects have limited their success as monotherapies in chronic cases. Combination strategies and hybrid molecules have demonstrated the potential to enhance efficacy and mitigate drug resistance. Despite challenges in achieving complete parasite clearance and managing potential toxicity, interdisciplinary efforts across medicinal chemistry, parasitology, and clinical research highlight the significant potential of triazoles as components of next-generation, patient-friendly antiparasitic regimens. These findings support the further optimization and clinical evaluation of triazole-based agents to improve treatments for neglected parasitic diseases.

30 October 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RCRenzo Carlucci
Renzo Carlucci
MLMaría-Natalia Lisa
María-Natalia Lisa
GLGuillermo Roberto Labadie
Guillermo Roberto Labadie

12 September 2024 in Archiv der Pharmazie
Verified
Journal Article
Closed access
ARAlejandro I. Recio-Balsells
Alejandro I. Recio-Balsells
RCRenzo Carlucci
Renzo Carlucci
SGSimone Giovannuzzi
Simone Giovannuzzi
FCFabrizio Carta
Fabrizio Carta
Claudiu SupuranClaudiu Supuran
Claudiu Supuran
GLGuillermo Roberto Labadie
Guillermo Roberto Labadie